IQVIA

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
IQVIA Holdings, Inc.
TypePublic
IndustryContract Research Organization
Pharmaceutical Service Consulting
Founded1982; 40 years ago (1982)
HeadquartersDanbury, Connecticut, U.S.
Durham, North Carolina, U.S.
Key people
Dennis Gillings
(Founder)
Ari Bousbib
(Chairman & CEO)
ProductsSupport services for pharmaceutical, biotech and medical companies and individuals
RevenueIncreaseUS$11.359 billion (2020)[1]
Increase US$308 million (2020)[1]
Total assetsIncrease US$24.6 billion (2020)[1]
Total equityIncrease US$49.57 billion (2021)[1]
Number of employees
99,000+ [1] (2021)
Websiteiqvia.com

IQVIA, formerly Quintiles and IMS Health, Inc.,[2] is an American multinational company serving the combined industries of health information technology and clinical research. IQVIA is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services. It has a network of more than 88,000 employees in more than 100 countries and a market capitalization of $49 Billion as of August 2021.[2] As of 2017, IQVIA was reported to be one of the world's largest contract research organizations.[3]

History[edit]

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider [4] The name of the modern company honors the legacy organizations. IQVIA: I (IMS Health), Q (Quintiles), and VIA (by way of).

IMS Health[edit]

IMS Health was best known for its collection of healthcare information spanning sales, de-identified prescription data, medical claims, electronic medical records[5] and social media.[6] IMS Health's products and services were used by companies to develop commercialization plans[7] and portfolio strategies,[8] to select patient and physician populations for specific therapies, and to measure the effectiveness of pharmaceutical marketing and sales resources.[9] The firm used its data to produce syndicated reports such as market forecasts and market intelligence.

The original name of the company was Intercontinental Marketing Statistics, hence the IMS name. IMS Health's corporate headquarters were located in Danbury, Connecticut, United States. Ari Bousbib was the chairman and CEO of IMS Health before the merger.

  • In 1998, the parent company, Cognizant Corporation, split into two companies: IMS Health and Nielsen Media Research. After this restructuring, Cognizant Technology Solutions became a public subsidiary of IMS Health
  • In 2002, IMS Health acquired Cambridge Pharma Consultancy, a privately held international firm that provides strategic advice to pharmaceutical management.
  • In 2003, acquired Marketing Initiatives, a specialist in healthcare facility profile data, and Data Niche Associates, a provider of rebate validation services for Medicaid and managed care. In 2003, IMS Health sold its entire 56% stake in Cognizant and both companies are separated into two independent entities as IMS Health and Cognizant
  • In 2004, United Research China Shanghai was acquired, providing coverage of China's consumer health market.
  • In 2005, acquired PharMetrics, a U.S. provider of patient-centric integrated claims data.
  • In 2006, acquired the Life Sciences practice of Strategic Decisions Group, a portfolio strategy consultant to the life sciences industry.
  • In 2007, IMS Health acquired IHS and MedInitiatives, providers of healthcare data management analytics and technology services. That same year, ValueMedics Research was acquired, extending IMS Health's health economics and outcomes research capabilities.
  • In 2007, ranked in the Businessweek 50. This list represents "best in class" companies from the ten economic sectors that make up the S&P 500.[10]
  • In 2008, named to the World's Most Admired Companies list by Fortune. The company received the recognition again in 2010.
  • In 2008, acquired RMBC, a provider of national pharmaceutical market intelligence and analytics in Russia.
  • In 2008, acquired the Skura professional services group, based out of Mississauga, Ontario, Canada and specialized in data integration, consulting, and services in business intelligence platforms to pharmaceutical and healthcare clients in North America and Europe.
  • In 2009, named to the Dow Jones Sustainability North America Index in recognition of the company's economic, environmental and social performance among the largest 600 North American companies.
  • In February 2010, IMS Health was taken private by TPG Capital, CPP Investment Board, and Leonard Green & Partners.[11]
  • In 2010, acquired Brogan, Inc., a privately held market research and consulting firm serving the Canadian healthcare market.
  • In 2011, expanded its specialty and patient-level data assets in the United States with the acquisition of SDI Health. Also that year, the company acquired Ardentia Ltd in the UK, and Med-Vantage in the United States to build on its payer services in those markets.
  • In 2012, acquired PharmARC Analytic Solutions Pvt. Ltd, a Bangalore-based analytics company.
  • In 2012, acquired DecisionView, a software solutions company that helps life sciences organizations plan and track patient enrollment for clinical trials[12] and TTC,[13] a benchmarking solutions and analytics company that helps clients plan for and negotiate the costs of clinical trials. Also in 2012, the company purchased PharmaDeals Ltd.,[14] a provider of online information about business transactions, licensing, and mergers and acquisitions activity within the pharmaceutical industry.[citation needed]
  • In 2013, acquired several companies to expand its portfolio of SaaS products: Incential Software, a provider of sales performance management technology services; 360 Vantage, which delivers multi-channel CRM software capabilities; Appature, which offers a relationship marketing platform; and Semantelli, a provider of social media analytics for the global healthcare industry.
  • In May 2015, IMS increased its software development capability by acquiring Dataline Software Ltd, a bespoke software development company and big data research specialist in the UK.[15]
  • In April 2015, IMS Health completed the purchase of Cegedim's Customer Relationship Management (CRM) software and Strategic Data business for €396 million. Cegedim acquired the software and related business when it purchased Dendrite International in 2007.[16][circular reference]
  • In August 2015, IMS Health completed the purchase of Boston Biomedical Consultants, a provider of market data and market research covering the in vitro Diagnostics market[17]

Quintiles[edit]

Quintiles was the world’s largest provider of biopharmaceutical development and commercial outsourcing services. The company offered clinical data management, clinical trial execution services, pharmaceuticals, drug development, financial partnering, and commercialization expertise to companies in the biotechnology, pharmaceutical and healthcare sectors.

In 1982, Dennis Gillings founded and incorporated Quintiles Transnational in North Carolina.[18] Quintiles Transnational established Quintiles Pacific Inc. and Quintiles Ireland Ltd. in 1990.[19] In 1991 Quintiles GmbH was established in Germany and Quintiles Laboratories Ltd. was established in Atlanta, Georgia.[20] In September 1996, Quintiles purchased Innovex Ltd. of Britain for $747.5 million in stock.[21] Quintiles went public in 1997 and completed a successful secondary stock offering.[22]

  • In 1974, Dennis Gillings signs the first contract to provide statistical and data management consulting for pharmaceutical clients.
  • In 1982, Quintiles, Inc., is incorporated in North Carolina.
  • In 1990, Quintiles Pacific Inc. and Quintiles Ireland Ltd. are established.
  • In 1991, Quintiles GmbH is established in Germany; Quintiles Laboratories Ltd. is established in Atlanta, Georgia.
  • In 1996, Quintiles buys Innovex Ltd. and BRI International Inc., becoming the world’s largest CRO.
  • In 1997, Quintiles goes public, completing a successful secondary stock offering.
  • In 1998, Quintiles becomes the first company in the industry to break the $1 billion mark, when it reports net revenues of $1.19 billion.
  • In 1999, the company joins the S&P 500 Index.
  • In 2003, the Board of Directors agrees to merge with Pharma Services Holdings Inc; Quintiles becomes a private company.
  • In 2009, Quintiles opens new corporate headquarters in Durham, North Carolina.
  • In 2010, Quintiles opens new European headquarters in the UK and establishes operations in East Africa.
  • In 2011, Quintiles buys Advion Biosciences, a bioanalytical lab based out of Ithaca, New York.
  • In 2013, Quintiles filed for an IPO on 15 February in order to go public again; Quintiles begins trading on the New York Stock Exchange (NYSE) under ticker symbol Q.”

IMS Health and Quintiles become IQVIA[edit]

In May 2016, Quintiles agreed plans to merge with IMS Health in a deal worth $9 billion dollars[23][24] IMS Health shareholders received 0.384 shares of Quintiles common stock for each share of IMS Health common stock they held, leaving the split of ownership at 51.4% IMS and 48.6% Quintiles.[25][26] The merger was completed in October and the resulting company was a $17.6 billion company called QuintilesIMS.[27] In November 2017, the company adopted the new name of IQVIA, and changed its ticker symbol on the NYSE from Q to IQV.[2]

Controversies[edit]

Throughout its history, the legacy IMS Health's business of collecting anonymized pharmaceutical sales data came under scrutiny from both the media and the legal system.[28]

IMS Health v. Ayotte was a free speech case involving IMS Health.[29][30][31]

Sorrell v. IMS Health Inc. was a case about physician-data privacy, which went to the U.S. Supreme Court. The High Court ruled in favor of the company.[32][33][34][35]

IQVIA was contracted by the UK government's Office of National Statistics to provide data on the prevalence of Covid-19 infection in the population. Some users of the survey reported problems contacting IQVIA and arranging for testing.[36] The problems with how the survey results were collected were criticised for potentially leading to biased data by New Scientist.[37]

References[edit]

  1. ^ a b c d e "☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934" (PDF). U.S. Securities and Exchange Commission. Retrieved 29 September 2018.
  2. ^ a b c "QuintilesIMS is now IQVIA". Business Wire. 6 November 2017. Retrieved 6 November 2017.
  3. ^ Melissa Fassbender (9 November 2017). "QuintilesIMS now IQVIA as it aims to 'outpace the inevitable progress of change'". Outsourcing-Pharma.com; William Reed Business Media Ltd. Retrieved 17 December 2017.
  4. ^ Henderson, Jennifer (3 October 2016). "Quintiles, IMS Health complete merger". Triangle Business Journal, American City Business Journals. Retrieved 3 October 2016.
  5. ^ "What Does IMS Health Do, Anyway?". The Wall Street Journal. 5 November 2009.
  6. ^ Munro, Dan. "New Study Ranks Johnson & Johnson #1 In Pharma For Social Media Engagement". Forbes.
  7. ^ Drive to Develop New Commercial Models.pdf "The Drive to Develop New Commercial Models"
  8. ^ in the News/Documents/Kleinrock, 2011 CA Biomed Industry Report_FINAL.pdf "CA Biomed Industry Report"
  9. ^ Market Maps TL.pdf "Patient Market Maps"
  10. ^ "The Business Week 50" Bloomberg Business Week, Accessed 20 October 2010
  11. ^ "TPG and Pension Plan to Buy IMS Health" New York Times Deal Book, 5 November 2009
  12. ^ Leuty, Ron (24 April 2012). "IMS Health to buy clinical trials software company Decision View". San Francisco Business Times. Retrieved 2020-11-16.
  13. ^ Conn, Joseph (2012-08-15). "IMS acquires analytics company TTC". Modern Healthcare. Retrieved 2020-11-16.
  14. ^ "IMS Health Expands Suite of Syndicated, Web-based Analytics With Acquisition of PharmaDeals Ltd". FiercePharma. 14 August 2012. Retrieved 2020-11-16.
  15. ^ "IMS Health Acquires Dataline Software, Extending Real-World Evidence Technology Platform and Application Suite". IMS Health. 2015-11-11. Retrieved 2017-05-25.
  16. ^ "Cegedim completes disposal of the CRM and Strategic Data Division to IMS Health" (PDF). 1 April 2015.
  17. ^ "Acquisition announcement" (PDF).
  18. ^ Matthew Herper (November 22, 2010). "Money, Math and Medicine". Forbes Magazine. Retrieved July 21, 2011.
  19. ^ "Quintiles Pacific, Inc.: Private Company Information - Businessweek". Bloomberg News.
  20. ^ "Quintiles Laboratories Limited: Private Company Information - Businessweek". Bloomberg News.
  21. ^ Derdak T, Atkins, W (2005). "Quintiles Transnational Corp". Encyclopedia.com.{{cite web}}: CS1 maint: uses authors parameter (link)
  22. ^ Olivia Oran (9 May 2013). "Quintiles IPO raises more-than-planned $947 million as stocks rally". Reuters.
  23. ^ "Quintiles is merging with IMS in a deal worth about $9 billion - Fortune". Fortune. Reuters. 3 May 2016.
  24. ^ "Quintiles, IMS Health Plan $9B Merger". GEN. 3 May 2016.
  25. ^ Kristen Hallam; Zachary Tracer (3 May 2016). "IMS Health to Buy Quintiles in $9 Billion Pharma Data Deal". Bloomberg.com.
  26. ^ Erik Holm (3 May 2016). "Deals of the Day: IMS Health Merges With Quintiles, Biogen to Spin Off Hemophilia Arm". WSJ.
  27. ^ Henderson, Jennifer (3 October 2016). "Quintiles, IMS Health complete merger". Triangle Business Journal, American City Business Journals. Retrieved 3 October 2016.
  28. ^ "Company that Knows What Drugs Everyone Takes Going Public". Forbes.
  29. ^ Baxter, Alexander D. "IMS Health v. Ayotte: A New Direction on Commercial Speech Cases" (PDF). Berkeley Technology Law Journal. 25 (1): 649–670. Archived from the original (PDF) on 5 November 2010. Retrieved 5 February 2014.
  30. ^ Shapiro, Ilya (28 April 2009). "IMS Health v. Ayotte | Cato Institute". cato.org. Cato Institute. Retrieved 5 February 2014.
  31. ^ Bibet-Kalinyak, Isabelle (2012). "Critical Analysis of Sorrell v. IMS Health, Inc.: Pandora's Box at Best". Food & Drug L.J. 67: 191.
  32. ^ "IMS Health Wins Court Attack on Vermont Marketing Law". Bloomberg. 23 November 2010.
  33. ^ Law360 11 August, 2011. Inside Sorrell V. IMS Health
  34. ^ Adam Liptak for the New York Times. 23 June 2011 Drug Makers Win Two Supreme Court Decisions
  35. ^ Gayland Hethcoat Regulating Pharmaceutical Marketing After Sorrell v. IMS Health Inc. Quinnipiac Health Law Journal. 2012 Vol. 15:187
  36. ^ Vaughan, Adam. "UK's vital covid-19 infection tracking survey deluged by complaints". New Scientist. Retrieved 2021-07-13.
  37. ^ Vaughan, Adam. "UK's official statisticians had concerns over covid-19 survey bias". New Scientist. Retrieved 2021-07-13.

External links[edit]